R01 DK104936/DK/NIDDK NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2016	1
2018	2
2019	3
2020	2
2021	2
2022	1
2024	0

1

Is there a causal relationship between obesity and puberty?

Reinehr T, Roth CL. Reinehr T, et al. Lancet Child Adolesc Health. 2019 Jan;3(1):44-54. doi: 10.1016/S2352-4642(18)30306-7. Epub 2018 Nov 14. Lancet Child Adolesc Health. 2019. PMID: 30446301 Review.

2

Hypothalamic Obesity: Prologue and Promise.

Abuzzahab MJ, Roth CL, Shoemaker AH. Abuzzahab MJ, et al. Horm Res Paediatr. 2019;91(2):128-136. doi: 10.1159/000496564. Epub 2019 Mar 18. Horm Res Paediatr. 2019. PMID: 30884480 Free article. Review.

3

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.

Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, Roth CL, Abuzzahab MJ. Shoemaker AH, et al. Int J Obes (Lond). 2022 Mar;46(3):623-629. doi: 10.1038/s41366-021-01043-6. Epub 2022 Jan 3. Int J Obes (Lond). 2022. PMID: 34975146 Free PMC article. Clinical Trial.

4

Connections Between Obesity and Puberty: Invited by Manuel Tena-Sempere, Cordoba.

Huang A, Reinehr T, Roth CL. Huang A, et al. Curr Opin Endocr Metab Res. 2020 Oct;14:160-168. doi: 10.1016/j.coemr.2020.08.004. Epub 2020 Aug 27. Curr Opin Endocr Metab Res. 2020. PMID: 33043167 Free PMC article.

5

Central Nervous System and Peripheral Hormone Responses to a Meal in Children.

Roth CL, Melhorn SJ, Elfers CT, Scholz K, De Leon MRB, Rowland M, Kearns S, Aylward E, Grabowski TJ, Saelens BE, Schur EA. Roth CL, et al. J Clin Endocrinol Metab. 2019 May 1;104(5):1471-1483. doi: 10.1210/jc.2018-01525. J Clin Endocrinol Metab. 2019. PMID: 30418574 Free PMC article.

6

Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.

Chepurny OG, Bonaccorso RL, Leech CA, Wöllert T, Langford GM, Schwede F, Roth CL, Doyle RP, Holz GG. Chepurny OG, et al. Sci Rep. 2018 Feb 28;8(1):3749. doi: 10.1038/s41598-018-22106-1. Sci Rep. 2018. PMID: 29491394 Free PMC article.

7

A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.

Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ. Roth CL, et al. Diabetes Obes Metab. 2021 Feb;23(2):363-373. doi: 10.1111/dom.14224. Epub 2020 Oct 25. Diabetes Obes Metab. 2021. PMID: 33026160 Free PMC article. Clinical Trial.

8

Activation of nuclear factor kappa B pathway and reduction of hypothalamic oxytocin following hypothalamic lesions.

Roth CL, D'Ambrosio G, Elfers C. Roth CL, et al. J Syst Integr Neurosci. 2016 Feb;2(1):79-84. doi: 10.15761/JSIN.1000114. Epub 2016 Jan 29. J Syst Integr Neurosci. 2016. PMID: 27512604 Free PMC article.

9

MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.

Perez FA, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ, Roth CL. Perez FA, et al. Diabetes Obes Metab. 2021 Jul;23(7):1532-1541. doi: 10.1111/dom.14366. Epub 2021 Mar 29. Diabetes Obes Metab. 2021. PMID: 33651438 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year